Attached files
| file | filename |
|---|---|
| EX-99 - EXHIBIT 99 - CANTEL MEDICAL LLC | cmd7312017ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 28, 2017
CANTEL MEDICAL CORP.
(Exact name of registrant as specified in its charter)
Delaware | 001-31337 | 22-1760285 |
(State or other jurisdiction | (Commission | (IRS Identification |
of incorporation) | File Number) | Number) |
150 Clove Road, Little Falls, New Jersey | 07424 |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (973) 890-7220
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition
On September 28, 2017, the Registrant issued a press release announcing its results of operations for the quarter ended July 31, 2017 (Registrant’s fourth quarter of fiscal year 2017). A copy of the press release is included with this Report as Exhibit 99.1.
Item 9.01 Financial Statements, Pro-Forma Financial Information and Exhibits
(d) Exhibit 99.1 Press release of Registrant dated September 28, 2017.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
CANTEL MEDICAL CORP. | ||
By: | /s/ Jorgen B. Hansen | |
Jorgen B. Hansen | ||
President and CEO | ||
September 28, 2017 | ||
3